lncRNA HIF1A‑AS2: A potential oncogene in human cancers (Review)

Liu,Yang; Zhang,Yunyan; Chen,Cha; Li,Youqiang

doi:10.3892/br.2021.1461

lncRNA HIF1A‑AS2: A potential oncogene in human cancers (Review)

Authors:
- Yang Liu
- Yunyan Zhang
- Cha Chen
- Youqiang Li
View Affiliations

Affiliations: The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510006, P.R. China, Department of Stomatology, Guangzhou Women and Children's Medical Center, Guangzhou, Guangdong 510000, P.R. China, Department of Laboratory Medicine, The Affiliated Hexian Memorial Hospital of Southern Medical University, Guangzhou, Guangdong 511400, P.R. China
Published online on: August 13, 2021 https://doi.org/10.3892/br.2021.1461
Article Number: 85
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Long non‑coding RNAs (lncRNAs) are transcripts that are >200 nucleotides, but with no open reading frame. An increasing number of lncRNAs have been identified following the development of second‑generation sequencing technologies, and they have since become a research hotspot. Functionally, they play a vital role in tumor progression, including in tumor proliferation, migration, invasion, apoptosis and acquisition of drug resistance. They regulate gene expression primarily through interaction with DNA, RNA and proteins at the epigenetic, transcriptional and post‑transcriptional levels. Endogenous hypoxia‑inducible factor 1α antisense RNA 2 (lncRNA HIF1A‑AS2) is aberrantly expressed and involved the development/progression of various types of tumors, such as bladder cancer, glioblastoma, breast cancer and osteosarcoma. It plays a vital role in the proliferation, apoptosis, migration, invasion and epithelial‑mesenchymal transformation of various tumor cells. This review summarizes the current body of knowledge on the biological functions and related molecular mechanisms of lncRNA HIF1A‑AS2 in the development/progression of human tumors and other diseases.

View Figures

View References

1	Slack FJ and Chinnaiyan AM: The role of non-coding RNAs in oncology. Cell. 179:1033–1055. 2019.PubMed/NCBI View Article : Google Scholar
2	Esteller M: Non-coding RNAs in human disease. Nat Rev Genet. 12:861–874. 2011.PubMed/NCBI View Article : Google Scholar
3	Khandelwal A, Bacolla A, Vasquez KM and Jain A: Long non-coding RNA: A new paradigm for lung cancer. Mol Carcinog. 54:1235–1251. 2015.PubMed/NCBI View Article : Google Scholar
4	Mercer TR, Dinger ME and Mattick JS: Long non-coding RNAs: Insights into functions. Nat Rev Genet. 10:155–159. 2009.PubMed/NCBI View Article : Google Scholar
5	Bhat SA, Ahmad SM, Mumtaz PT, Malik AA, Dar MA, Urwat U, Shah RA and Ganai NA: Long non-coding RNAs: Mechanism of action and functional utility. Noncoding RNA Res. 1:43–50. 2016.PubMed/NCBI View Article : Google Scholar
6	Thrash-Bingham CA and Tartof KD: aHIF: A natural antisense transcript overexpressed in human renal cancer and during hypoxia. J Natl Cancer Inst. 91:143–151. 1999.PubMed/NCBI View Article : Google Scholar
7	Rossignol F, Vaché C and Clottes E: Natural antisense transcripts of hypoxia-inducible factor 1alpha are detected in different normal and tumour human tissues. Gene. 299:135–140. 2002.PubMed/NCBI View Article : Google Scholar
8	Chen WM, Huang MD, Kong R, Xu TP, Zhang EB, Xia R, Sun M, De W and Shu YQ: Antisense long noncoding RNA HIF1A-AS2 is upregulated in gastric cancer and associated with poor prognosis. Dig Dis Sci. 60:1655–1662. 2015.PubMed/NCBI View Article : Google Scholar
9	Lin H, Zhao Z, Hao Y and He J and He J: Long noncoding RNA HIF1A-AS2 facilitates cell survival and migration by sponging miR-33b-5p to modulate SIRT6 expression in osteosarcoma. Biochem Cell Biol. 98:284–292. 2020.PubMed/NCBI View Article : Google Scholar
10	Wu P, Haththotuwa R, Kwok CS, Babu A, Kotronias RA, Rushton C, Zaman A, Fryer AA, Kadam U, Chew-Graham CA, et al: Preeclampsia and future cardiovascular health: A systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes. 10(e003497)2017.PubMed/NCBI View Article : Google Scholar
11	Phipps EA, Thadhani R, Benzing T and Karumanchi SA: Pre-eclampsia: Pathogenesis, novel diagnostics and therapies (vol 15, pg 275, 2019). Nat Rev Nephrol. 15:386. 2019.PubMed/NCBI View Article : Google Scholar
12	Irminger-Finger I, Jastrow N and Irion O: Preeclampsia: A danger growing in disguise. Int J Biochem Cell Biol. 40:1979–1983. 2008.PubMed/NCBI View Article : Google Scholar
13	Ma Y, Liang X, Wu H, Zhang C and Ma Y: Long non coding RNA NR_002794 is upregulated in pre eclampsia and regulates the proliferation, apoptosis and invasion of trophoblast cells. Mol Med Rep. 20:4567–4575. 2019.PubMed/NCBI View Article : Google Scholar
14	Wu D, Yang N, Xu Y, Wang S, Zhang Y, Sagnelli M, Hui B, Huang Z and Sun L: lncRNA HIF1A antisense RNA 2 modulates trophoblast cell invasion and proliferation through upregulating PHLDA1 expression. Mol Ther Nucleic Acids. 16:605–615. 2019.PubMed/NCBI View Article : Google Scholar
15	Tang X, Liu S, Liu Y, Lin X, Zheng T, Liu X, Qiu J and Hua K: Circulating serum exosomal aHIF is a novel prognostic predictor for epithelial ovarian cancer. Onco Targets Ther. 12:7699–7711. 2019.PubMed/NCBI View Article : Google Scholar
16	Guler E, Smith DA, Somarouthu B, Gujrathi R, Ramaiya NH and Tirumani SH: Overview of imaging findings associated with systemic therapies in advanced epithelial ovarian cancer. Abdom Radiol (NY). 45:828–841. 2020.PubMed/NCBI View Article : Google Scholar
17	Lheureux S, Braunstein M and Oza AM: Epithelial ovarian cancer: Evolution of management in the era of precision medicine. CA Cancer J Clin. 69:280–304. 2019.PubMed/NCBI View Article : Google Scholar
18	Qiu JJ, Lin XJ, Zheng TT, Tang XY and Hua KQ: Natural antisense transcript of hypoxia-inducible factor 1 regulates hypoxic cell apoptosis in epithelial ovarian cancer. Onco Targets Ther. 11:9101–9110. 2018.PubMed/NCBI View Article : Google Scholar
19	Yang J, McDowell A, Kim EK, Seo H, Lee WH, Moon CM, Kym SM, Lee DH, Park YS, Jee YK, et al: Development of a colorectal cancer diagnostic model and dietary risk assessment through gut microbiome analysis. Exp Mol Med. 51:1–15. 2019.PubMed/NCBI View Article : Google Scholar
20	Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global patterns and trends in colorectal cancer incidence and mortality. Gut. 66:683–691. 2017.PubMed/NCBI View Article : Google Scholar
21	Yuan W, Peng S, Wang J, Wei C, Ye Z, Wang Y, Wang M, Xu H, Jiang S, Sun D, et al: Identification and characterization of circRNAs as competing endogenous RNAs for miRNA-mRNA in colorectal cancer. PeerJ. 7(e7602)2019.PubMed/NCBI View Article : Google Scholar
22	Dong Y, Zhang Y, Kang W, Wang G, Chen H, Higashimori A, Nakatsu G, Go M, Tong JH, Zheng S, et al: VSTM2A suppresses colorectal cancer and antagonizes Wnt signaling receptor LRP6. Theranostics. 9:6517–6531. 2019.PubMed/NCBI View Article : Google Scholar
23	Lin J, Shi Z, Yu Z and He Z: lncRNA HIF1A-AS2 positively affects the progression and EMT formation of colorectal cancer through regulating miR-129-5p and DNMT3A. Biomed Pharmacother. 98:433–439. 2018.PubMed/NCBI View Article : Google Scholar
24	Fan H, Jin X, Liao C, Qiao L and Zhao W: MicroRNA-301b-3p accelerates the growth of gastric cancer cells by targeting zinc finger and BTB domain containing 4. Pathol Res Pract. 215(152667)2019.PubMed/NCBI View Article : Google Scholar
25	Wan P, Bai X, Yang C, He T, Luo L, Wang Y, Fan M, Wang Z, Lu L, Yin Y, et al: miR-129-5p inhibits proliferation, migration, and invasion in rectal adenocarcinoma cells through targeting E2F7. J Cell Physiol. 235:5689–5701. 2020.PubMed/NCBI View Article : Google Scholar
26	Wang LL, Zhang L and Cui XF: Downregulation of long noncoding RNA LINC01419 inhibits cell migration, invasion, and tumor growth and promotes autophagy via inactivation of the PI3K/Akt1/mTOR pathway in gastric cancer. Ther Adv Med Oncol. 11(1758835919874651)2019.PubMed/NCBI View Article : Google Scholar
27	Lee KL, Kuo YC, Ho YS and Huang YH: Triple-negative breast cancer: Current understanding and future therapeutic breakthrough targeting cancer Stemness. Cancers (Basel). 11(1334)2019.PubMed/NCBI View Article : Google Scholar
28	Khan MA, Jain VK, Rizwanullah M, Ahmad J and Jain K: PI3K/AKT/mTOR pathway inhibitors in triple-negative breast cancer: A review on drug discovery and future challenges. Drug Discov Today. 24:2181–2191. 2019.PubMed/NCBI View Article : Google Scholar
29	Song N, Zhao L, Zhu M and Zhao J: 99mTc-Labeled LyP-1 for SPECT Imaging of Triple Negative Breast Cancer. Contrast Media Mol Imaging. 2019(9502712)2019.PubMed/NCBI View Article : Google Scholar
30	Guo X, Lee S and Cao P: The inhibitive effect of sh-HIF1A-AS2 on the proliferation, invasion, and pathological damage of breast cancer via targeting miR-548c-3p through regulating HIF-1α/VEGF pathway in vitro and vivo. Onco Targets Ther. 12:825–834. 2019.PubMed/NCBI View Article : Google Scholar
31	Jiang YZ, Liu YR, Xu XE, Jin X, Hu X, Yu KD and Shao ZM: Transcriptome Analysis of triple-negative breast cancer reveals an integrated mRNA-lncRNA signature with predictive and prognostic value. Cancer Res. 76:2105–2114. 2016.PubMed/NCBI View Article : Google Scholar
32	Yu G, Zhou H, Yao W, Meng L and Lang B: lncRNA TUG1 promotes cisplatin resistance by regulating CCND2 via epigenetically silencing miR-194-5p in bladder cancer. Mol Ther Nucleic Acids. 16:257–271. 2019.PubMed/NCBI View Article : Google Scholar
33	Miao L, Liu HY, Zhou C and He X: LINC00612 enhances the proliferation and invasion ability of bladder cancer cells as ceRNA by sponging miR-590 to elevate expression of PHF14. J Exp Clin Cancer Res. 38(143)2019.PubMed/NCBI View Article : Google Scholar
34	Zhuang C, Ma Q, Zhuang C, Ye J, Zhang F and Gui Y: lncRNA GClnc1 promotes proliferation and invasion of bladder cancer through activation of MYC. FASEB J. 33:11045–11059. 2019.PubMed/NCBI View Article : Google Scholar
35	Chen M, Zhuang C, Liu Y, Li J, Dai F, Xia M, Zhan Y, Lin J, Chen Z, He A, et al: Tetracycline-inducible shRNA targeting antisense long non-coding RNA HIF1A-AS2 represses the malignant phenotypes of bladder cancer. Cancer Lett. 376:155–164. 2016.PubMed/NCBI View Article : Google Scholar
36	Qi X, Yu XJ, Wang XM, Song TN, Zhang J, Guo XZ, Li GJ and Shao M: Knockdown of KCNQ1OT1 suppresses cell invasion and sensitizes osteosarcoma cells to CDDP by upregulating DNMT1-mediated Kcnq1 expression. Mol Ther Nucleic Acids. 17:804–818. 2019.PubMed/NCBI View Article : Google Scholar
37	Jiang N, Wang X, Xie X, Liao Y, Liu N, Liu J, Miao N, Shen J and Peng T: lncRNA DANCR promotes tumor progression and cancer stemness features in osteosarcoma by upregulating AXL via miR-33a-5p inhibition. Cancer Lett. 405:46–55. 2017.PubMed/NCBI View Article : Google Scholar
38	Zhang CL, Zhu KP and Ma XL: Antisense lncRNA FOXC2-AS1 promotes doxorubicin resistance in osteosarcoma by increasing the expression of FOXC2. Cancer Lett. 396:66–75. 2017.PubMed/NCBI View Article : Google Scholar
39	Zhong L, Liao D, Li JJ, Liu WQ, Wang JX, Zeng CL, Wang X, Cao ZL, Zhang RH, Li M, et al: Rab22a-NeoF1 fusion protein promotes osteosarcoma lung metastasis through its secretion into exosomes. Signal Transduct Target Ther. 6(59)2021.PubMed/NCBI View Article : Google Scholar
40	Wang X, Peng L, Gong X, Zhang X and Sun R: lncRNA HIF1A-AS2 promotes osteosarcoma progression by acting as a sponge of miR-129-5p. Aging (Albany NY). 11:11803–11813. 2019.PubMed/NCBI View Article : Google Scholar
41	Tang C, Wang Y, Zhang L, Wang J, Wang W, Han X, Mu C and Gao D: Identification of novel lncRNA targeting Smad2/PKCα signal pathway to negatively regulate malignant progression of glioblastoma. J Cell Physiol. 235:3835–3848. 2020.PubMed/NCBI View Article : Google Scholar
42	Ji J, Xu R, Ding K, Bao G, Zhang X, Huang B, Wang X, Martinez A, Wang X, Li G, et al: Long Noncoding RNA SChLAP1 forms a growth-promoting complex with HNRNPL in human glioblastoma through stabilization of ACTN4 and activation of NF-κB signaling. Clin Cancer Res. 25:6868–6881. 2019.PubMed/NCBI View Article : Google Scholar
43	Mineo M, Ricklefs F, Rooj AK, Lyons SM, Ivanov P, Ansari KI, Nakano I, Chiocca EA, Godlewski J and Bronisz A: The Long Non-coding RNA HIF1A-AS2 facilitates the maintenance of mesenchymal glioblastoma stem-like cells in hypoxic niches. Cell Rep. 15:2500–2509. 2016.PubMed/NCBI View Article : Google Scholar
44	Wang L, Babikir H, Müller S, Yagnik G, Shamardani K, Catalan F, Kohanbash G, Alvarado B, Di Lullo E, Kriegstein A, et al: The phenotypes of proliferating glioblastoma cells reside on a single axis of variation. Cancer Discov. 9:1708–1719. 2019.PubMed/NCBI View Article : Google Scholar
45	Bhat KPL, Balasubramaniyan V, Vaillant B, Ezhilarasan R, Hummelink K, Hollingsworth F, Wani K, Heathcock L, James JD, Goodman LD, et al: Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma. Cancer Cell. 24:331–346. 2013.PubMed/NCBI View Article : Google Scholar
46	Liao K, Ma X, Chen B, Lu X, Hu Y, Lin Y, Huang R and Qiu Y: Upregulated AHIF-mediated radioresistance in glioblastoma. Biochem Biophys Res Commun. 509:617–623. 2019.PubMed/NCBI View Article : Google Scholar
47	Kovacs G, Wilkens L, Papp T and de Riese W: Differentiation between papillary and nonpapillary renal cell carcinomas by DNA analysis. J Natl Cancer Inst. 81:527–530. 1989.PubMed/NCBI View Article : Google Scholar
48	Korenaga Y, Naito K, Okayama N, Hirata H, Suehiro Y, Hamanaka Y, Matsuyama H and Hinoda Y: Association of the BCRP C421A polymorphism with nonpapillary renal cell carcinoma. Int J Cancer. 117:431–434. 2005.PubMed/NCBI View Article : Google Scholar
49	Zhang C, Huang D, Liu A, Xu Y, Na R and Xu D: Genome-wide screening and cohorts validation identifying novel lncRNAs as prognostic biomarkers for clear cell renal cell carcinoma. J Cell Biochem. 121:2559–2570. 2020.PubMed/NCBI View Article : Google Scholar
50	Zhu Y, Yang Z, Chen H, Pan Y, Gong L, Chen F, Jin X, Wen S, Li Y and Chen G: lncRNAHIF1A-AS2 promotes renal carcinoma cell proliferation and migration via miR-130a-5p/ERBB2 pathway. Onco Targets Ther. 13:9807–9820. 2020.PubMed/NCBI View Article : Google Scholar
51	The Lancet: Lung cancer: Some progress, but still a lot more to do. The Lancet. 394(1880)2019.PubMed/NCBI View Article : Google Scholar
52	Ramalingam SS, Owonikoko TK and Khuri FR: Lung cancer: New biological insights and recent therapeutic advances. CA Cancer J Clin. 61:91–112. 2011.PubMed/NCBI View Article : Google Scholar
53	Dawson Q: NELSON trial: Reduced lung-cancer mortality with volume CT screening. Lancet Respir Med. 8:236. 2020.PubMed/NCBI View Article : Google Scholar
54	Zhang W, Liu K, Pei Y, Tan J, Ma J and Zhao J: Long noncoding RNA HIF1A-AS2 promotes non-small cell lung cancer progression by the miR-153-5p/S100A14 axis. Onco Targets Ther. 13:8715–8722. 2020.PubMed/NCBI View Article : Google Scholar
55	Wang P: The Opening of Pandora's Box: An emerging role of long noncoding RNA in viral infections. Front Immunol. 9(3138)2019.PubMed/NCBI View Article : Google Scholar
56	Mu L, Wang Y, Su H, Lin Y, Sui W, Yu X and Lv Z: HIF1A-AS2 promotes the proliferation and metastasis of gastric cancer cells through miR-429/PD-L1 axis. Dig Dis Sci Feb 8, 2021 (Epub ahead of print). doi: 10.1007/s10620-020-06819-w.